Oncothyreon Inc. (ONTY)

Oncology Corporate Profile

Stock Performance

1.2900
-0.0200

HQ Location

2601 Fourth Avenue, Suite 500
Seattle, WA 98121

Company Description

Oncothyreon is a biotechnology company dedicated to the development of oncology products that can improve the lives and outcomes of cancer patients. Oncothyreon_†ós pipeline includes both synthetic vaccines and small molecules for a variety of cancer indications. The company_†_s flagship product is Stimuvax¥Ô, a cancer vaccine currently in Phase III development for non-small cell lung cancer. Oncothyreon collaborates with Merck & Co Inc. for the clinical development and marketing of Stimuvax. Oncothyreon_†_s group of clinical and pre-clinical stage propriety products consist of PX-478, a Phase I trial product, which is a small molecule inhibitor for advanced metastatic cancer; PX-866, an inhibitor for advanced solid tumors and glioma; PX-12, a Phase II trial product for pancreatic cancer; and PX-316, a chemical inhibitor that prevents translocation. Oncothyreon was founded in 1985.

Website: http://www.oncothyreon.com

This company does not have any commercial products

This company does not have any pipeline products

Pipeline image

Source


http://oncothyreon.com

Recent News Headlines

Oncothyreon Announces Corporate Name Change to Cascadian Therapeutics (NASDAQ: CASC)

6/8/2016 11:49 am

(Cascadian Therapeutics) June 8, 2016 - The new name reflects the change in the Company’s focus from therapeutic vaccines to advancing targeted treatments for cancer.

Oncothyreon Presents Phase 1b Results of ONT-380 in Combination with T-DM1 in HER2+ Metastatic Breast Cancer at ASCO

6/5/2016 06:24 pm

(Oncothyreon) June 5, 2016 - Encouraging results in ONT-380 combination therapy in patients with and without brain metastases.

Aprepitant Decreases Cough in Patients With Lung Cancer

10/14/2015 11:04 am

(Medscape Medical News) Oct 13, 2015 - Aprepitant (Emend, Merck & Co, Inc), a drug approved for chemotherapy-induced nausea and vomiting, has shown promise as an antitussive agent in a small trial of patients with lung cancer.

Breast Cancer Drug Tamoxifen May Offer Powerful Punch Against Killer Superbugs: Study

10/14/2015 11:04 am

(Washington Post/To Your Health) Oct 13, 2015 - A study published in Nature Communications raises the possibility that a promising new weapon for MRSA may have been right under our noses: tamoxifen.

Armed Malaria Protein Found to Kill Cancer Cells

10/14/2015 11:04 am

(Centre for Drug Research and Development [Vancouver, BC]) Oct 13, 2015 - A new type of cancer therapy based on seemingly unrelated elements of malaria and cancer is showing promise for development.

TAK-733 Shows Challenge Of Using A Promising Drug In The Human Body

10/14/2015 11:04 am

(UCCC/Colorado Cancer Blogs) Oct 13, 2015 - A University of Colorado Cancer Center study recently published online ahead of print in the journal Oncotarget reports “robust antitumor activity” of the drug TAK-733 in cells and mouse models of colorectal cancer.

Oncothyreon Breast Cancer Drug Exits ASCO '15 with Good Buzz

6/1/2015 06:07 pm

(TheStreet) June 1, 2015 - Combinations of medicines including Oncothyreon's ONT-380 induced meaningful tumor shrinkage in breast cancer patients who entered the study because they were no longer responding to multiple prior therapies.

Oncothyreon Announces Presentation of Positive ONT-380 Data in HER2-Positive Breast Cancer at ASCO Annual Meeting and Updates Development Plan

5/30/2015 06:26 pm

(TheStreet) May 30, 2015 - Oncothyreon Inc. today announced the presentation of positive data from the company's ongoing trials of ONT-380, an orally active, reversible and selective small-molecule HER2 inhibitor for the treatment of breast cancer, at the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting.

Incyte Sponsors First Observational Study Designed to Understand the Impact of Polycythemia Vera – a Rare, Progressive Blood Cancer

2/26/2015 12:01 pm

(NASDAQ) Feb 26, 2015 - Incyte Corporation today announced that it is sponsoring the first major observational study of patients living with polycythemia vera (PV) in the U.S.

Oncothyreon Announces Exclusive License Agreement With Array BioPharma For ONT-380

12/12/2014 02:59 pm

(CNNMoney) Dec 12, 2014 - Oncothyreon Inc. today announced that Array BioPharma Inc. has granted Oncothyreon an exclusive license to develop, manufacture and commercialize ONT-380 (ARRY-380), an orally active, reversible and selective small molecule HER2 inhibitor.

Oncothyreon Announces Presentation of Positive ONT-380 Data at San Antonio Breast Cancer Symposium

12/12/2014 02:42 pm

(Yahoo! Finance) Dec 12, 2014 - Oncothyreon Inc. today announced that positive preliminary data from two ongoing Phase 1b trials of ONT-380 (ARRY-380), an orally active, reversible and selective small molecule HER2 inhibitor, will be presented at the San Antonio Breast Cancer Symposium.

Oncothyreon Cancer Drug Test in Japan Shows 'No Treatment Effect,' Stock Falls

8/19/2014 12:22 pm

(Puget Sound Business Journal/Health Care NW blog) Aug 19, 2014 - Bellevue biotech Oncothyreon Inc. said a test of its lung cancer drug in Japan "did not meet its primary endpoint of an improvement in overall survival, and no treatment effect was seen."

ASCO '14: Foundation Medicine Builds Case for Insurance Coverage

6/2/2014 02:00 pm

(TheStreet) June 2, 2014 - Foundation Medicine released the results of its decision analytics study earlier Saturday morning at the American Society of Clinical Oncology annual meeting, demonstrating 27.3% of doctors altered their prescriptions based on a FoundationOne diagnostic test.

F.D.A. Approves Celebrex in Generic Versions

5/31/2014 12:04 pm

(New York Times/Associated Press) May 30, 2014 – The Food and Drug Administration on Friday approved the first generic versions of Pfizer’s anti-inflammatory painkiller Celebrex.

Clinical Trial Analysis Suggests Drug Combination May Be Highly Effective in Recurrent Ovarian Cancer

5/31/2014 12:01 pm

(Dana-Farber) May 31, 2014 - Significant improvement with the use of a combination drug therapy for recurrent ovarian cancer was reported at the annual meeting of the American Society of Clinical Oncology (ASCO) meeting in Chicago today.

Oncothyreon and Celldex Therapeutics Announce Collaboration for Combination Immunotherapy Clinical Trial of ONT-10 and Varlilumab

5/29/2014 11:44 am

(Yahoo! Finance) May 29, 2014 - Oncothyreon Inc. and Celldex Therapeutics, Inc. today announced that they have agreed to collaborate on a combined clinical trial of ONT-10 and varlilumab. ONT-10 is a therapeutic vaccine targeting the tumor-associated antigen MUC1.

Advaxis Selects inVentiv Health Clinical to Conduct Clinical Trials of Immunotherapy Candidates

5/29/2014 07:00 am

(MarketWatch) May 29, 2014 - Advaxis, Inc., a biotechnology company developing cancer immunotherapies, and inVentiv Health Clinical, a leading global clinical research organization (CRO), announced today that they have entered into a master services agreement for the clinical development of certain immunotherapy product candidates in Advaxis's proprietary pipeline.

Oncothyreon and Celldex Therapeutics Announce Collaboration for Combination Immunotherapy Clinical Trial of ONT-10 and Varlilumab

5/29/2014 06:04 am

(Yahoo! Finance) May 29, 2014 - Oncothyreon Inc. and Celldex Therapeutics, Inc. today announced that they have agreed to collaborate on a combined clinical trial of ONT-10 and varlilumab. ONT-10 is a therapeutic vaccine targeting the tumor-associated antigen MUC1.

Cambridge Cancer Firm Lines Up $174m Bonanza

4/22/2014 12:00 pm

(Business Weekly [UK]) Apr 22, 2014 - Medical technology from Cambridge UK cancer business Sentinel Oncology is being developed and commercialised by US company Oncothyreon in a collaboration that could bring the Science Park firm mega-millions.

Oncothyreon and Array BioPharma Announce Initiation of Phase 1b Trial of ONT-380 in Combination with TDM-1 in Patients with Metastatic HER2+ Breast Cancer

2/20/2014 11:55 am

(Denver Post) Feb 20, 2014 - Oncothyreon Inc. and Array BioPharma Inc. today announced the initiation of a Phase 1b trial of ONT-380 (ARRY-380) in combination with Kadcyla® (ado-trastuzumab emtansine or TDM-1) in patients with metastatic HER2+ breast cancer.

Oncothyreon and Array BioPharma Announce Initiation of Phase 1b Trial of ONT-380 in Combination with TDM-1 in Patients with Metastatic HER2+ Breast Cancer

2/20/2014 11:05 am

(Denver Post) Feb 20, 2014 - Oncothyreon Inc. and Array BioPharma Inc. today announced the initiation of a Phase 1b trial of ONT-380 (ARRY-380) in combination with Kadcyla® (ado-trastuzumab emtansine or TDM-1) in patients with metastatic HER2+ breast cancer.

Oncothyreon and Array BioPharma Announce Initiation of Phase 1b Trial of ONT-380 in Combination with Capecitabine and/or Trastuzumab in Patients with Metastatic HER2+ Breast Cancer

2/3/2014 11:52 am

(Yahoo! Finance) Feb 3, 2014 - Oncothyreon Inc. and Array BioPharma Inc. today announced the initiation of a Phase 1b trial of ONT-380 (ARRY-380) in combination with Xeloda® (capecitabine) and/or Herceptin® (trastuzumab) in patients with metastatic HER2+ breast cancer.

Oncothyreon and Array BioPharma Announce Initiation of Phase 1b Trial of ONT-380 in Combination with Capecitabine and/or Trastuzumab in Patients with Metastatic HER2+ Breast Cancer

2/3/2014 11:05 am

(Yahoo! Finance) Feb 3, 2014 - Oncothyreon Inc. and Array BioPharma Inc. today announced the initiation of a Phase 1b trial of ONT-380 (ARRY-380) in combination with Xeloda® (capecitabine) and/or Herceptin® (trastuzumab) in patients with metastatic HER2+ breast cancer.

New Position Created to Oversee Memorial Sloan-Kettering’s Regional Care Network and Alliance

10/18/2013 11:03 am

(MSKCC) Oct 17, 2013 - Memorial Sloan-Kettering Cancer Center has announced the appointment of surgical oncologist Richard Barakat to the new position of Deputy Physician-in-Chief for the Memorial Sloan-Kettering Regional Care Network and Alliance.

Oncothyreon Says ONT-380 Showed Acceptable Safety Profile

10/7/2013 11:50 am

(Morningstar/Benzinga) Oct 7, 2013 - Oncothyreon Inc. today announced the presentation of final results from the first Phase 1 trial of ONT-380 at the American Association for Cancer Research Special Conference on Advances in Breast Cancer Research in San Diego.

Oncothyreon Says ONT-380 Showed Acceptable Safety Profile

10/7/2013 11:05 am

(Morningstar/Benzinga) Oct 7, 2013 - Oncothyreon Inc. today announced the presentation of final results from the first Phase 1 trial of ONT-380 at the American Association for Cancer Research Special Conference on Advances in Breast Cancer Research in San Diego.

Oncothyreon Announces Initiation of Phase 1 Trial of ONT-380 in Combination with Trastuzumab in Patients with Brain Metastases from HER2+ Breast Cancer

9/4/2013 11:22 am

(KOLD-TV, Ch. 13/Tucson News Now [Tucson, AZ]) Sep 3, 2013 - Oncothyreon Inc. today announced the initiation of an investigator-sponsored trial of ONT-380 in combination with trastuzumab (Herceptin®) in patients with brain metastases from HER2+ breast cancer.

Oncothyreon Announces Initiation of Phase 1 Trial of ONT-380 in Combination with Trastuzumab in Patients with Brain Metastases from HER2+ Breast Cancer

9/4/2013 11:02 am

(KOLD-TV, Ch. 13/Tucson News Now [Tucson, AZ]) Sep 3, 2013 - Oncothyreon Inc. today announced the initiation of an investigator-sponsored trial of ONT-380 in combination with trastuzumab (Herceptin®) in patients with brain metastases from HER2+ breast cancer.

Epigenetic Factor Likely Plays a Key Role in Fueling Most Common Childhood Cancer

6/12/2013 11:03 am

(St. Jude) June 10, 2013 - Changes in an epigenetic mechanism that turns expression of genes on and off may be as important as genetic alterations in causing pediatric acute lymphoblastic leukemia (ALL), according to a study led by scientists at St. Jude Children’s Research Hospital and published in the June 10 online edition of the Journal of Clinical Investigation.

More Breast-Feeding Could Save Billions and Prevent Thousands of Breast Cancer Cases

6/7/2013 10:00 am

(Time Healthland) June 7, 2013 - If new moms adhered to the recommended guidelines that urge them to breast-feed each child they give birth to for at least one year, they could theoretically stave off up to 5,000 cases of breast cancer annually.

Oncothyreon, Array in Deal to Commercialize Cancer Drug

5/30/2013 11:38 am

(Puget Sound Business Journal) May 30, 2013 - Oncothyreon Inc. said it's signed a deal with Array BioPharma Inc. of Boulder, Colo. to commercialize Array's breast-cancer drug.

Oncothyreon, Array in Deal to Commercialize Cancer Drug

5/30/2013 11:03 am

(Puget Sound Business Journal) May 30, 2013 - Oncothyreon Inc. said it's signed a deal with Array BioPharma Inc. of Boulder, Colo. to commercialize Array's breast-cancer drug.

ASCO '13 Preview: Oncothyreon's Failed Lung Cancer Vaccine

5/16/2013 12:32 pm

(The Street) May 15, 2013 - New details about failed lung cancer immunotherapy from Oncothyreon were revealed for the first time Wednesday night in a research abstract for the American Society of Clinical Oncology (ASCO) annual meeting.

ASCO '13 Preview: Oncothyreon's Failed Lung Cancer Vaccine

5/16/2013 12:03 pm

(The Street) May 15, 2013 - New details about failed lung cancer immunotherapy from Oncothyreon were revealed for the first time Wednesday night in a research abstract for the American Society of Clinical Oncology (ASCO) annual meeting.

Oncothyreon's PX-866 Misses PFS Endpoint in NSCLC

5/13/2013 11:56 am

(BioCentury) May 10, 2013 - Oncothyreon Inc. disclosed in its 1Q13 earnings late Thursday that once-daily oral PX-866 plus docetaxel missed the primary endpoint of improving progression-free survival (PFS) vs. docetaxel alone in a cohort of patients with non-small cell lung cancer (NSCLC) in the open-label Phase II portion of a Phase I/II trial to treat advanced metastatic solid tumors.

Oncothyreon's PX-866 Misses PFS Endpoint in NSCLC

5/13/2013 11:05 am

(BioCentury) May 10, 2013 - Oncothyreon Inc. disclosed in its 1Q13 earnings late Thursday that once-daily oral PX-866 plus docetaxel missed the primary endpoint of improving progression-free survival (PFS) vs. docetaxel alone in a cohort of patients with non-small cell lung cancer (NSCLC) in the open-label Phase II portion of a Phase I/II trial to treat advanced metastatic solid tumors.

ASCO U.S. Members: Please Help ASCO Monitor and Assess Drug Shortages’ Impact on Cancer Care

3/22/2013 11:01 am

(ASCO in Action) Mar 21, 2013 - ASCO members should have received an invitation on March 16 to participate in an oncology drug shortages survey to help ASCO and its membership understand the impact of drug shortages.

Gamekeeper or Poacher? - Big Pharma's Stance on Biosimilars

2/7/2013 12:03 pm

(Forbes) Feb 6, 2013 - On Thursday (February 7), Amgen management will discuss the company’s future growth strategies at an eagerly awaited business review day. One particular area of interest – for investors and analysts alike – will be discussion on how Amgen is looking to develop its role in the biosimilars market.

Merck KGaA, Oncothyreon Lung Cancer Drug Fails Late-Stage Study

12/19/2012 07:47 am

(TheStreet) Dec 19, 2012 - Stimuvax, an experimental cancer immunotherapy from Merck KGaA and Oncothyreon, failed to improve survival in a late-stage study of non-small cell lung cancer patients, the companies announced Wednesday.

Merck KGaA, Oncothyreon Lung Cancer Drug Fails Late-Stage Study

12/19/2012 07:04 am

(TheStreet) Dec 19, 2012 - Stimuvax, an experimental cancer immunotherapy from Merck KGaA and Oncothyreon, failed to improve survival in a late-stage study of non-small cell lung cancer patients, the companies announced Wednesday.

First 90 Days of 2013 Are Live or Die For These Biotech Stocks

11/19/2012 12:02 pm

(TheStreet) Nov 19, 2012 - The first quarter of 2013 is shaping up to be action-packed for biotech investors.